Chaccour 2021.

Study characteristics
Methods	Trial design: double‐blind RCT with 2 parallel arms Type of publication: journal publication Setting: outpatient Recruitment dates: July to September 2020 Country: Spain Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: NCT04390022 Date of registration: 15 May 2020
Participants	Number of participants (randomized/analyzed): 24/24 Age (median): overall 28 years Males, n: overall 12 (50%) Severity of condition according to study definition: outpatients with non‐severe symptoms Severity of condition according to WHO scale: 2 to 3 Co‐morbidities: existing co‐morbidity was specified as exclusion criterion. Virus detection performed at baseline (test‐positive at baseline): RT‐PCR (100%) Inclusion criteria: consecutive outpatients attending the emergency department of the Clinica Universidad de Navarra (Pamplona, Spain) with symptoms compatible with COVID‐19; no more than 72 hours of fever or cough; positive PCR for SARS‐CoV‐2 Exclusion criteria: positive IgG against SARS‐CoV‐2; co‐morbidities considered risk factors for severe disease or COVID‐19 pneumonia at baseline
Interventions	Details of intervention Type and dose: ivermectin 0.4 mg/kg, single dose Route of administration: oral Treatment details of control group Placebo Concomitant therapy: NA Duration of follow‐up: 28 days Treatment cross‐overs: none
Outcomes	Primary study outcome Proportion of patients with a positive SARS‐CoV‐2 PCR Relevant review outcomes reported Mortality at 28 days Viral clearance (RT‐PCR, E‐gene) at 7 days Adverse events within 28 days Serious adverse events within 28 days Additional study outcomes reported Viral load evolution within 21 days Viral clearance (RT‐PCR, N‐gene) at 7 days Patient‐days of any symptoms, cough, and ansomia IgG‐titres at 21 days
Notes	Date of publication: 23 February 2021 Sponsor/funding: departmental resources Additional results posted in registry Information on ethics votum: name of responsible ethics committee, reference number of proposal, and votum provided by author via personal correspondence